Vildagliptin
- Generic Name
- Vildagliptin
- Brand Names
- Galvus, Jalra, Xiliarx
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O2
- CAS Number
- 274901-16-5
- Unique Ingredient Identifier
- I6B4B2U96P
- Background
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependen...
- Indication
Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thi...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.
- Conditions
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- SatRx LLC
- Target Recruit Count
- 299
- Registration Number
- NCT03088670
- Locations
- 🇷🇺
State Budget Educational Institution higher professional education "Saratov State Medical University n.a. V.I. Razumovsky" of the Ministry of Healthcare of Russian Federation based on Clinical Hospital n.a S.R. Mirotvortsev, Saratov, Russian Federation
🇷🇺State Educational Institution of Higher Professional Education "Perm State Medical Academy n.a. academician EA Wagner's "Ministry of Health of the Russian Federation on the basis of Department of Endocrinology Regional Clinical Hospital, Perm, Russian Federation
🇷🇺State Health Care Institution Leningrad Regional Hospital, Saint Petersburg, Russian Federation
Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Peking University
- Target Recruit Count
- 100
- Registration Number
- NCT02999841
- Locations
- 🇨🇳
Beijing Pinggu Hospital, Beijing, Beijing, China
A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2019-04-02
- Target Recruit Count
- 203
- Registration Number
- NCT02853630
- Locations
- 🇮🇳
Jnana Sanjeevini Medical Centre, Bangalore, Karnataka, India
🇮🇳Dr V.Seshiah Diabetes research Institute, Dr V.Balaji Diabetes care centre, Chennai, Tamil Nadu, India
🇮🇳Vikas Pai Research Foundation, Pune, Maharashtra, India
Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period
- Conditions
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 186
- Registration Number
- NCT02849899
- Locations
- 🇫🇷
CHU de Besançon, Besançon, France
Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Genuine Research Center, Egypt
- Target Recruit Count
- 24
- Registration Number
- NCT02816970
- Locations
- 🇪🇬
Genuine Research Center GRC, Cairo, Egypt
Monotherapy With Rapamycin in Long-standing Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- Piemonti Lorenzo
- Target Recruit Count
- 55
- Registration Number
- NCT02803892
- Locations
- 🇮🇹
IRCCS San Raffaele Scientific Institute, Milan, Italy
Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion
- Conditions
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Michael A. Nauck
- Target Recruit Count
- 24
- Registration Number
- NCT02749032
- Locations
- 🇩🇪
Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Niedersachsen, Germany
Vildagliptin Versus Dapagliflozin on Glucagon
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2019-05-02
- Lead Sponsor
- Lund University
- Target Recruit Count
- 28
- Registration Number
- NCT02475070
- Locations
- 🇸🇪
Lund University, Lund, Sweden
Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin
- Conditions
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 443
- Registration Number
- NCT02343926
- Locations
- 🇷🇺
Investigational Site 03, Vladimir, Vladimirskaya Oblast, Russian Federation
Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension
- Conditions
- Interventions
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Dr. José Fernando Vilela-Martin MD PhD
- Target Recruit Count
- 50
- Registration Number
- NCT02145611
- Locations
- 🇧🇷
Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.